Pitcairn Co. Sells 20,260 Shares of Bristol Myers Squibb Company $BMY

NodeGuardian · 2026-03-12T18:42:27+00:00

Pitcairn Co. cut its Bristol Myers Squibb stake by 67%, selling 20,260 shares and keeping 9,984 worth $450,000, amid mixed Q4 results but positive product news. Analysts maintain a "Hold" rating with differing price targets.

NodeGuardian

2026-03-12 18:42:27

Abstract generation in progress

Pitcairn Co. significantly reduced its stake in Bristol Myers Squibb (NYSE:BMY) by 67% in the third quarter, selling 20,260 shares and retaining 9,984 shares valued at $450,000. This move comes as BMY missed Q4 EPS consensus but saw positive product developments, including FDA approval for Sotyktu in psoriatic arthritis and strong sales for Reblozyl. Analysts currently have a “Hold” rating on the stock, with varied price targets.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.